Source-grounded facts extracted from Sanara MedTech Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Sanara MedTech Inc. shareholders approved Advisory vote on the frequency of future advisory votes on named executive officer compensation at the 2026-06-04 meeting.
“Proposal 4 : Approval, on an advisory basis, of the frequency of future advisory votes on named executive officer compensation.”
Sanara MedTech Inc. shareholders approved Advisory approval of the compensation of the Company’s named executive officers at the 2026-06-04 meeting.
“Proposal 3: Approval, on an advisory basis, of the compensation of the Company’s named executive officers.”
Sanara MedTech Inc. shareholders approved Ratification of the appointment of Weaver and Tidwell, L.L.P. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-04 meeting.
“Proposal 2 : Ratification of the appointment of Weaver and Tidwell, L.L.P. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Sanara MedTech Inc. shareholders approved Election of nine directors to serve for a one-year term until 2027 annual meeting at the 2026-06-04 meeting.
“Proposal 1 : Election of (i) Seth D. Yon, (ii) Ronald T. Nixon, (iii) Robert A. DeSutter, (iv) Roszell Mack III, (v) Eric D. Major, (vi) Keith G. Myers, (vii) Sara N. Ortwein, (viii) Ann Beal Salamone and (ix) Eric D. Tanzberger to the Board of Directors of the Company, each to serve for a one-year term until the annual meeting of shareholders to be held in 2027 and until his or her successor is elected and qualified.”
Sanara MedTech Inc. terminated Services Agreement with The Catalyst Group, Inc. (effective 2026-06-02).
“On June 2, 2026, in connection with the Company’s shift in strategy to focus on soft tissue repair and bone fusion products for the surgical market, the Company entered into a Mutual Termination Agreement (the “Mutual Termination Agreement”) with Catalyst, pursuant to which the parties agreed to terminate the Services Agreement, effective immediately.”
Sanara MedTech Inc. reported the first quarter ended March 31, 2026 results: revenue $27.8 million, net income $0.4 million, EPS $0.04 per diluted share.
“in the surgical market, today reported its financial results for the first quarter ended March 31, 2026. First Quarter 2026 Financial Summary (1) ● Net revenue increased 19% to $27.8 million, compared to $23.4 million in the first quarter of 2025. ● Gross profit of $25.9 million, or 93% of net revenue, compared to gross profit of $21.6 million, or 92% of net”
Sanara MedTech Inc. reported the fourth quarter and full year ended December 31, 2025 results: revenue $27.5 million, net income Net loss from continuing operations of $1.1 million. Guidance reaffirmed.
“December 31, 2025, and reaffirmed its financial guidance for the full year ending December 31, 2026. Fourth Quarter 2025 Financial Summary (1 ) ● Net revenue increased 5% to $27.5 million, compared to $26.3 million in the fourth quarter of 2024. ○ As previously disclosed, the Company experienced growth in sales of BIASURGE ® Advanced Surgical Solution”
Elizabeth B. Taylor changed role as Chief Financial Officer at Sanara MedTech Inc..
“On the Effective Date, Elizabeth B. Taylor, the Company’s Chief Financial Officer, will assume Mr. McNeil’s duties as principal accounting officer.”
Michael D. McNeil departed as Chief Accounting Officer and Chief Administrative Officer at Sanara MedTech Inc..
“On May 19, 2025, Michael D. McNeil notified Sanara MedTech Inc. (the “Company”) that he is retiring from his position as Chief Accounting Officer and Chief Administrative Officer of the Company, effective August 19, 2025”
Sanara MedTech Inc. completed an acquisition involving CarePICS, LLC and its unit holders for $2.0 million (closed 2025-04-01).
“barriers to care and make a lasting impact on the patients it serves. Cash Consideration Pursuant to the Purchase Agreement, the aggregate purchase price for the Acquisition was $2.0 million, which included transaction expenses and other related administrative expenses of the Sellers. On the Closing Date, the Company also paid $1.65 million to satisfy certain”
Elizabeth B. Taylor was appointed as Chief Financial Officer at Sanara MedTech Inc..
“On January 15, 2025 (the “Effective Date”), the Board of Directors (the “Board”) of Sanara MedTech Inc. (the “Company”) appointed Elizabeth B. Taylor to serve as the Chief Financial Officer of the Company, including the role of principal financial officer, effective as of the Effective Date.”
Keith Myers was appointed as Director at Sanara MedTech Inc..
“On October 4, 2024, the Board appointed Keith Myers as a director of the Company, effective October 4, 2024 (the “Effective Date”), to fill the vacancy resulting from Mr. Stuckert’s resignation.”
James W. Stuckert resigned as Director at Sanara MedTech Inc..
“On October 4, 2024, James W. Stuckert notified Sanara MedTech Inc. (the “Company”) of his intention to resign from his position as a member of the Company’s Board of Directors (the “Board”) and each of its committees upon which he serves, effective as of October 4, 2024.”
Zachary B. Fleming resigned as Chief Executive Officer at Sanara MedTech Inc..
“Zachary B. Fleming tendered his resignation as the Chief Executive Officer of Sanara MedTech Inc. (the “Company”), effective as of such date”
Sanara MedTech Inc. reported the quarter ended March 31, 2024 results: revenue $18.5 million, net income net loss of $1.8 million.
“resources as well as add to the executive team.” Strategic and Operational Highlights in the First Quarter 2024 ● In the first quarter of 2024, the Company generated a record $18.5 million in sales, representing a tenth consecutive record revenue quarter for the Company. ● For the three months ended March 31, 2024, the Company had a net loss of $1.8 million,”
Ronald T. Nixon was appointed as Chief Executive Officer at Sanara MedTech Inc..
“On May 12, 2024, the Board appointed Ronald T. Nixon, the Company’s Executive Chairman, as the Chief Executive Officer of the Company, effective immediately.”
Zachary B. Fleming departed as Chief Executive Officer at Sanara MedTech Inc..
“On May 10, 2024 (the “Effective Date”), Zachary B. Fleming delivered notice to the Board of Directors of the Company (the “Board”) that he is resigning from his position as Chief Executive Officer of the Company, effective immediately.”
Sanara MedTech Inc. incurred term loan of up to $55.0 million with CRG Servicing LLC at 13.25% maturing March 30, 2029.
“On April 17, 2024 (the “Closing Date”), Sanara MedTech Inc. (the “Company”) entered into a Term Loan Agreement (the “Loan Agreement”), by and among the Company, as borrower, the subsidiary guarantors party thereto from time to time (collectively, the “Guarantors”), CRG Servicing LLC, as administrative agent and collateral agent (the “Agent”), and the lenders party thereto from time to time, providing for a senior secured term loan of up to $55.0 million (the “Loan”).”
Sanara MedTech Inc. entered into Loan Agreement with CRG Servicing LLC valued at up to $55.0 million (effective 2024-04-17).
“Sanara MedTech Inc. (the “Company”) entered into a Term Loan Agreement (the “Loan Agreement”), by and among the Company, as borrower, the subsidiary guarantors party thereto from time to time (collectively, the “Guarantors”), CRG Servicing LLC, as administrative agent and collateral agent (the “Agent”), and the lenders party thereto from time to time, providing for a senior secured term loan of up to $55.0 million (the “Loan”).”
Jacob A. Waldrop was appointed as Chief Operating Officer at Sanara MedTech Inc..
“On April 5, 2024, Sanara MedTech Inc. (the “Company”) announced that the Board of Directors (the “Board”) of the Company appointed Mr. Jacob A. Waldrop as the Chief Operating Officer of the Company, effective April 15, 2024 (the “Effective Date”).”
Sanara MedTech Inc. reported the year ended December 31, 2023 results: revenue $65.0 million, net income net loss of $4.4 million.
“For the year ended December 31, 2023, Sanara generated net revenues of $65.0 million”
Sanara MedTech Inc. reported the quarter and year ended December 31, 2023 results: revenue $17.7 million, net income net loss of $0.3 million.
“outcomes and reduce costs throughout the U.S.” Strategic and Operational Highlights in the Fourth Quarter 2023 ● In the fourth quarter 2023, the Company generated a record $17.7 million in sales, representing a ninth record revenue quarter for the Company. ● For the three months ended December 31, 2023, the Company had a net loss of $0.3 million, compared to”
Sanara MedTech Inc.: Amended and restated bylaws effective immediately, including increased shareholder threshold for special meetings, advance notice provisions, director removal vote change, and other updates (effective 2024-03-21).
“On March 21, 2024, the Board of Directors (the “Board”) of Sanara MedTech Inc. (the “Company”) adopted amended and restated bylaws (the “Amended and Restated Bylaws”), effective immediately.”
Sanara MedTech Inc. reported preliminary financial results for fourth quarter and full year 2023.
“On February 22, 2024, Sanara MedTech Inc. (the “Company”) issued a press release announcing certain preliminary financial results for the fourth quarter and full year 2023.”
Sanara MedTech Inc. reported the quarter ended September 30, 2023 results: revenue $16.0 million, net income net loss of $1.1 million.
“that can improve outcomes while reducing healthcare expenditures.” Third Quarter 2023 Strategic and Operational Highlights (Unaudited) ● The Company generated net revenue of $16.0 million for the three months ended September 30, 2023, an eighth consecutive record sales quarter. ● The Company’s loss before income taxes for the three months ended September 30,”
Sanara MedTech Inc. reported the three months ended June 30, 2022 results: revenue $9.7 million, net income net income of $0.8 million.
“wound care uses and five trademarks. Sales Analysis The Company generated net revenues of $15.8 million for the three months ended June 30, 2023, compared to net revenues of $9.7 million for the three months ended June 30, 2022, a 63% increase from the prior year period. The higher net revenues for the three months ended June 30, 2023 were primarily due to”
Sanara MedTech Inc. reported the quarter ended June 30, 2023 results: revenue $15.8 million, net income net loss of $1.9 million.
“The Company generated net revenues of $15.8 million for the three months ended June 30, 2023”
Sanara MedTech Inc. completed an acquisition involving The Hymed Group Corporation and Applied Nutritionals, LLC for $15.25 million (closed 2023-08-01).
“HYCOL Hydrolyzed Collagen (Powder and Gel) (“HYCOL”) products for human wound care use. The Purchased Assets were purchased for an initial aggregate purchase price of $15.25 million, consisting of (i) $9.75 million in cash (the “Cash Closing Consideration”), (ii) 73,809 shares of the Company’s common stock, par value $0.001 per share (the “Stock Closing”
Sanara MedTech Inc. entered into Asset Purchase Agreement with The Hymed Group Corporation, Applied Nutritionals, LLC, and Dr. George D. Petito valued at initial aggregate purchase price of $15.25 million (effective 2023-08-01).
“On August 1, 2023, Sanara MedTech Inc., a Texas corporation (the “Company”), entered into an Asset Purchase Agreement (the “Purchase Agreement”) by and among the Company, as guarantor, Sanara MedTech Applied Technologies, LLC, a Texas limited liability company and wholly owned subsidiary of the Company (the “Purchaser”), The Hymed Group Corporation, a Delaware corporation (“Hymed”), Applied Nutritionals, LLC, a Delaware limited liability company (“Applied” and, together with Hymed, the “Sellers”), and Dr. George D. Petito (the “Owner”)”
Sanara MedTech Inc. shareholders approved Approval, on an advisory basis, of the compensation of the Company’s named executive officers. at the 2023-06-01 meeting.
“Proposal 3 : Approval, on an advisory basis, of the compensation of the Company’s named executive officers. Votes Cast For Votes Cast Against Abstentions Broker Non-Votes 5,548,532 24,489 888 1,791,319”
Sanara MedTech Inc. shareholders approved Ratification of the appointment of Weaver and Tidwell, L.L.P. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. at the 2023-06-01 meeting.
“Proposal 2 : Ratification of the appointment of Weaver and Tidwell, L.L.P. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. Votes Cast For Votes Cast Against Abstentions 6,140,532 0 0”
Sanara MedTech Inc. shareholders approved Election of (i) Ronald T. Nixon, (ii) Robert A. DeSutter, (iii) Roszell Mack III, (iv) Eric D. Major, (v) Sara N. Ortwein, (vi) Ann Beal Salamone, (vii) James W. Stuckert and (viii) Eric D. Tanzberger to the Company’s Board of Directors, each to serve for a one-year term until the annual meeting of at the 2023-06-01 meeting.
“Proposal 1 : Election of (i) Ronald T. Nixon, (ii) Robert A. DeSutter, (iii) Roszell Mack III, (iv) Eric D. Major, (v) Sara N. Ortwein, (vi) Ann Beal Salamone, (vii) James W. Stuckert and (viii) Eric D. Tanzberger to the Company’s Board of Directors, each to serve for a one-year term until the annual meeting of shareholders to be held in 2024 or until his or her successor is elected and qualified. Nominee Votes Cast For Votes Withheld Broker Non-Votes Ronald T. Nixon 5,547,819 0 1,817,409 Robert A. DeSutter 5,512,123 60,898 1,792,207 Roszell Mack III 5,556,796 16,225 1,792,207 Eric D. Major 5,556,796 16,225 1,792,207 Sara N. Ortwein 5,556,621 16,400 1,792,207 Ann Beal Salamone 5,555,763 17,258 1,792,207 James W. Stuckert 5,564,051 8,970 1,792,207 Eric D. Tanzberger 5,556,821 16,200 1,792,207”
Sanara MedTech Inc. reported the quarter ended March 31, 2023 results: revenue $15.5 million, net income net loss of $1.2 million.
“clearance for BIASURGETM. First Quarter 2023 Consolidated Financial Results (Unaudited) ● Net Revenues. For the three months ended March 31, 2023, we generated net revenues of $15.5 million compared to net revenues of $7.8 million for the three months ended March 31, 2022, a 99% increase from the prior year period. Our net revenues for the three months ended March”
Sanara MedTech Inc. reported the quarter and year ended December 31, 2022 results: revenue $45.8 million.
“for its Precision Healing Multispectral Imager Full Year 2022 Consolidated Financial Results ● Net Revenues. For the year ended December 31, 2022, we generated net revenues of $45.8 million compared to net revenues of $24.1 million for the year ended December 31, 2021, a 90% increase from the prior year. Our 2022 net revenues included $6.0 million of Scendia”
Sanara MedTech Inc. entered into Sales Agreement with Cantor Fitzgerald & Co. valued at up to $75,000,000 (effective 2023-02-24).
“On February 24, 2023, Sanara MedTech Inc., a Texas corporation (the “Company”), entered into a Controlled Equity Offering SM Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co., as sales agent (“Cantor”), pursuant to which the Company may offer and sell from time to time, to or through Cantor, shares of the Company’s common stock, par value $0.001 per share, having an aggregate offering price of up to $75,000,000 (the “Shares”).”
Sanara MedTech Inc. reported the fourth quarter and full year 2022 results: revenue approximately $15.3 million.
“preliminary results for the fourth quarter and full-year 2022. Selected Fourth Quarter and Full-Year 2022 Preliminary Results (Unaudited) ● Net revenue of approximately $15.3 million for the three months ended December 31, 2022, compared to net revenue of $7.0 million for the three months ended December 31, 2021, which would result in a record net revenue”
Shawn M. Bowman resigned as President, Strategic Partnerships at Sanara MedTech Inc..
“On December 2, 2022 (the “Effective Date”), Shawn M. Bowman tendered his resignation as President, Strategic Partnerships of Sanara MedTech Inc. (the “Company”), effective immediately.”
Sanara MedTech Inc. reported financial results for quarter ended September 30, 2022.
“On November 14, 2022, the Company furnished (i) a press release announcing its financial results for the quarter ended September 30, 2022 (the “Press Release”)”
Sanara MedTech Inc. reported the quarter ended September 30, 2022 results: revenue $13.0 million.
“For the three months ended September 30, 2022, the Company generated net revenues of $13.0 million compared to net revenues of $5.8 million for the three months ended September 30, 2021 representing a 124% increase from the prior year period.”
Zachary B. Fleming was appointed as Chief Executive Officer at Sanara MedTech Inc..
“appointed Mr. Zachary B. Fleming as the Chief Executive Officer of the Company, effective January 1, 2022.”
Zachary B. Fleming was appointed as Chief Executive Officer at Sanara MedTech Inc..
“On December 22, 2021, the Board of Directors (the “Board”) of Sanara MedTech Inc. (the “Company”) appointed Mr. Zachary B. Fleming as the Chief Executive Officer of the Company, effective January 1, 2021 (the “Effective Date”).”
Eric Tanzberger was appointed as Director at Sanara MedTech Inc..
“the Board appointed Eric Tanzberger as a director of the Company, effective January 1, 2022”
J. Michael Carmena resigned as Principal Executive Officer at Sanara MedTech Inc..
“Mr. Carmena delivered a letter providing notice of his resignation from his position as Principal Executive Officer of the Company and as a member of the Board of Directors (the “Board”), effective December 31, 2021.”
Roszell Mack III was appointed as Director at Sanara MedTech Inc..
“appointed Roszell Mack III as a director of the Company to fill the newly created vacancy, effective January 1, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.